{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-001714","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2023-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.785441+00:00","generated_at":"2026-06-20T14:43:10.770070+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Angion merges with Elicio in all-stock deal; Elicio holders to own 65.5% of combined company","bullets":["Elicio stockholders will own 65.5% and Angion stockholders 34.5% of combined company on a fully-diluted basis.","Combined company to focus on Elicio's ELI-002 therapeutic cancer vaccine targeting mKRAS-driven tumors, currently in Phase 1 trial.","Angion committed up to $10M bridge loan to Elicio in two installments; merger expected to close in Q2 2023.","Robert Connelly, CEO of Elicio, will be CEO of combined company; board will have 9 directors with 6 from Elicio and 3 from Angion.","Angion adopted retention bonus plan for CEO and CBO, providing cash bonuses and accelerated equity vesting upon closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-001714","json":"https://secwatch.observer/filing/0001140361-23-001714.json","markdown":"https://secwatch.observer/filing/0001140361-23-001714.md","text":"https://secwatch.observer/filing/0001140361-23-001714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/0001140361-23-001714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/ny20006674x1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T14:43:10.770070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a96eabc08ed620bc70e135a34e682879b786e3c6","claim":"Elicio Therapeutics, Inc. entered into Agreement and Plan of Merger and Reorganization with Angion Biomedica Corp. (effective 2023-01-17).","evidence_excerpt":"On January 17, 2023, Angion Biomedica Corp. , a Delaware corporation (“Angion”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Elicio Therapeutics, Inc., a Delaware corporation (“Elicio”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601485/000114036123001714/0001140361-23-001714-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Angion Biomedica Corp."},{"label":"Effective","value":"2023-01-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}